• 

  How New Alzheimer’s Drugs Are Changing the Game
• 

  Biogen Slashes Aduhelm Price; EMA Rejects It in EU
• 

  High Hopes, Low Sales: Aduhelm’s Dismal Roll-Out and What’s Next for Anti-Amyloids
• 

  Does Aduhelm Work? Patients Weigh In on the Controversial Alzheimer’s Drug
• 

  Gantenerumab for Alzheimer’s Gets FDA ‘Breakthrough’ Status
• 

  FDA Head Calls for Investigation Into Controversial Aduhelm Approval
• 

  FDA Speeds Up Process for Two More Anti-Amyloids
• 

  Q&A With Dr. Stephen Salloway: Implications of the FDA Aducanumab Decision
• 

  What’s Next for Eli Lilly Alzheimer’s Drug Donanemab? Trial Enrollment Continues
• 

  Does Eli Lilly’s Alzheimer’s Drug Donanemab Work? Key New Data Released
• 

  Experimental Alzheimer’s Drug Donanemab Looks Promising in Phase 2 Trial
• 

  ‘A4’ Study Aims Targets Amyloid in Alzheimer’s Earliest Stages

Previous34